"Indian companies are resisting to supply material without advance. Their money is stuck," a pharma industry analyst ... the Doklam impasse in 2017, India chose to become 'aatmanirbhar' (self ...

The Indian pharma market, currently valued at around USD 55 billion, is projected to expand 2.2 to 2.4 times over the next ...

Pharma companies are “highly vulnerable” to the ... generic drugs manufactured at sites in India will be produced using imported materials and be shipped to distributors worldwide, who will ...

From a humble beginnings in 1980s, Sun Pharma has grown to become one of the largest generic pharmaceutical companies worldwide, ultimately becoming the largest pharmaceutical company in India ...